Viewing Study NCT02446405

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:21 AM
Ignite Modification Date: 2026-03-11 @ 6:06 PM
Study NCT ID: NCT02446405
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-02-06
First Post: 2015-05-04
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Sponsor: University of Sydney
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Prostatic Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None metastatic prostate cancer View
None prostate cancer View
None prostate cancer treatment View
None enzalutamide View